A Single-Dose, Replicate Crossover Design Comparative Bioavailability Study of Dronabinol Oral Solution 5 mg Versus Marinol Capsules 5 mg Under Fasted Conditions

Trial Profile

A Single-Dose, Replicate Crossover Design Comparative Bioavailability Study of Dronabinol Oral Solution 5 mg Versus Marinol Capsules 5 mg Under Fasted Conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Dronabinol (Primary)
  • Indications Anorexia; Nausea and vomiting
  • Focus Pharmacokinetics
  • Sponsors INSYS Therapeutics, Inc
  • Most Recent Events

    • 07 Jun 2016 Results of comparative bioavailability study of dronabinol oral solution versus dronabinol capsules (n=52) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results assessing the effect of food on pharmacokinetics of dronabinol oral solution versus capsules (n=54) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 According to an Insys Therapeutics media release, a New Drug Application has been re-submitted to the US FDA. Earlier a 'Refusal to File' letter was received in October 2014 for previously submitted NDA due to inadequate or incomplete pediatric study plan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top